{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:27:21Z","timestamp":1789054041009,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005761","name":"University of Gothenburg Sahlgrenska Academy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsradet","doi-asserted-by":"publisher","award":["2018-02566"],"award-info":[{"award-number":["2018-02566"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015766","name":"Danone Nutricia Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015766","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"V\u00e4stra G\u00f6talandsregionen","doi-asserted-by":"publisher","award":["ALFGBG-726561"],"award-info":[{"award-number":["ALFGBG-726561"]}],"id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001610","name":"Falk Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.coph.2022.102284","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T08:07:14Z","timestamp":1662365234000},"page":"102284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome"],"prefix":"10.1016","volume":"66","author":[{"given":"Joost P.","family":"Algera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"T\u00f6rnblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Simr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2022.102284_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study","volume":"160","author":"Sperber","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/apt.12938","article-title":"Review article: the economic impact of the irritable bowel syndrome","volume":"40","author":"Canavan","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2022.102284_bib4","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41395-018-0262-x","article-title":"Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem","volume":"113","author":"\u00c5","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2022.102284_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrgastro.2014.200","article-title":"Crosstalk at the mucosal border: importance of the gut microenvironment in IBS","volume":"36","author":"\u00d6hman","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102284_bib6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1053\/j.gastro.2016.02.028","article-title":"The intestinal microenvironment and functional gastrointestinal disorders","volume":"150","author":"Barbara","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2018.07.011","article-title":"Rome foundation working team report on post-infection irritable bowel syndrome","volume":"156","author":"Barbara","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut microbiota in patients with irritable bowel syndrome\u2014a systematic review","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2016.09.049","article-title":"Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome","volume":"152","author":"Tap","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap8914","article-title":"Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome","volume":"10","author":"Vich Vila","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2022.102284_bib11","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.cell.2020.08.007","article-title":"Longitudinal multi-omics reveals subset-specific mechanisms underlying irritable bowel syndrome","volume":"182","author":"Mars","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.coph.2022.102284_bib12","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1053\/j.gastro.2021.06.024","article-title":"Mucosal biofilms are an endoscopic feature of irritable bowel syndrome and ulcerative colitis","volume":"161","author":"Baumgartner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2022.102284_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2018.1460013","article-title":"Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome","volume":"10","author":"Fodor","year":"2019","journal-title":"Gut Microb"},{"key":"10.1016\/j.coph.2022.102284_bib16","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/ctg.2016.32","article-title":"Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome","volume":"7","author":"Acosta","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.coph.2022.102284_bib17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","article-title":"Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats","volume":"146","author":"Xu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/gutjnl-2018-318160","article-title":"Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis","volume":"69","author":"Black","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102284_sref19","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.14309\/ajg.0000000000000444","article-title":"Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea","volume":"114","author":"Rezaie","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2022.102284_bib20","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2022.102284_bib21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1007\/s10620-014-3157-8","article-title":"Antibiotic treatment of constipation-predominant irritable bowel syndrome","volume":"59","author":"Pimentel","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2022.102284_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu11092162","article-title":"The dietary management of patients with irritable bowel syndrome: a narrative review of the existing and emerging evidence","volume":"11","author":"Algera","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.coph.2022.102284_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1440-1746.2009.06149.x","article-title":"Evidence-based dietary management of functional gastrointestinal symptoms: the FODMAP approach","volume":"25","author":"Gibson","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102284_bib24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/gut.48.1.14","article-title":"Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome","volume":"48","author":"Serra","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102284_bib25","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/nmo.12449","article-title":"Abnormal accumulation of intestinal fluid following ingestion of an unabsorbable carbohydrate in patients with irritable bowel syndrome: an MRI study","volume":"26","author":"Undseth","year":"2014","journal-title":"Neuro Gastroenterol Motil"},{"key":"10.1016\/j.coph.2022.102284_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.gastro.2016.09.062","article-title":"Colon hypersensitivity to distension, rather than excessive gas production, produces carbohydrate-related symptoms in individuals with irritable bowel syndrome","volume":"152","author":"Major","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib27","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/apt.16812","article-title":"Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome","volume":"55","author":"Wu","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2022.102284_bib28","first-page":"1510","article-title":"Fermentable carbohydrate restriction reduces luminal Bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome","volume":"142","author":"Staudacher","year":"2012","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.coph.2022.102284_bib29","article-title":"Long-term personalized low FODMAP diet improves symptoms and maintains luminal Bifidobacteria abundance in irritable bowel syndrome","volume":"34","author":"Staudacher","year":"2021","journal-title":"Neuro Gastroenterol Motil"},{"key":"10.1016\/j.coph.2022.102284_bib30","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/gutjnl-2016-313128","article-title":"Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs","volume":"67","author":"Bennet","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102284_bib31","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1136\/gutjnl-2021-325177","article-title":"Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet","volume":"71","author":"Vervier","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102284_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrgastro.2017.75","article-title":"Expert consensus document: the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics","volume":"14","author":"Gibson","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102284_bib33","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/ajcn\/nqy376","article-title":"Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"109","author":"Wilson","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.coph.2022.102284_bib34","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000276","article-title":"Human milk oligosaccharides support normal bowel function and improve symptoms of irritable bowel syndrome: a multicenter, open-label trial","volume":"11","author":"Palsson","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.coph.2022.102284_bib35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nrgastro.2014.66","article-title":"The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic","volume":"11","author":"Net","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102284_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.629026","article-title":"Pharmacological therapies and their clinical targets in irritable bowel syndrome with diarrhea","volume":"11","author":"Colomier","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coph.2022.102284_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101154","article-title":"Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"41","author":"McFarland","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.coph.2022.102284_bib38","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3390\/nu11092048","article-title":"Probiotics in irritable bowel syndrome: an up-to-date systematic review","volume":"11","author":"Dale","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.coph.2022.102284_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.gastro.2015.05.008","article-title":"Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook","volume":"149","author":"Kelly","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.15330","article-title":"Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome","volume":"50","author":"Ianiro","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2022.102284_sref41","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2021.2020067","article-title":"Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D","volume":"14","author":"Singh","year":"2022","journal-title":"Gut Microb"},{"key":"10.1016\/j.coph.2022.102284_sref42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2020.07.013","article-title":"Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial","volume":"160","author":"Holvoet","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2022.102284_bib43","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/apt.15740","article-title":"Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome","volume":"51","author":"Lahtinen","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2022.102284_sref44","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/gutjnl-2019-319630","article-title":"Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study","volume":"69","author":"El-Salhy","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102284_bib45","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S2468-1253(19)30198-0","article-title":"Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial","volume":"4","author":"Aroniadis","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102284_bib46","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000034","article-title":"The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study","volume":"10","author":"Holster","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.coph.2022.102284_bib47","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/gutjnl-2018-316434","article-title":"Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study","volume":"67","author":"Halkj\u00e6r","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.coph.2022.102284_bib48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(17)30338-2","article-title":"Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial","volume":"3","author":"Johnsen","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2022.102284_bib49","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/gutjnl-2020-321529","article-title":"FMT in IBS: a call for caution","volume":"70","author":"Camilleri","year":"2021","journal-title":"Gut"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489222001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:50:22Z","timestamp":1778615422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489222001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":49,"alternative-id":["S1471489222001114"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2022.102284","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2022.102284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102284"}}